$Pfizer(PFE)$ Pfizer will be a surefire winner in 2022 as a company regardless of what happens with the COVID-19 pandemic. It already has major supply deals lined up for its COVID-19 vaccine and pill that will generate billions of dollars in revenue. Pfizer's lineup also includes multiple other growth drivers like blood thinner Eliquis and rare heart disease drug Vyndaqel/Vyndamax.